Loading...
XNASSIBN
Market cap658mUSD
Jan 14, Last price  
15.70USD
1D
-3.27%
1Q
18.76%
IPO
-25.24%
Name

SI-BONE Inc

Chart & Performance

D1W1MN
XNAS:SIBN chart
P/E
—
P/S
4.74
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
19.30%
Rev. gr., 5y
20.19%
Revenues
139m
+30.52%
37,016,00048,999,00040,054,00041,173,00042,101,00047,983,00055,380,00067,301,00073,387,00090,152,000106,409,000138,886,000
Net income
-43m
L-31.11%
-10,903,000-6,154,000-27,806,000-28,154,000-20,589,000-23,039,000-17,453,000-42,576,000-48,542,000-60,128,000-62,903,000-43,336,000
CFO
-19m
L-55.08%
-14,759,000-566,000-26,327,000-26,718,000-16,753,000-17,530,000-14,519,000-31,627,000-30,662,000-39,533,000-41,655,000-18,713,000
Earnings
Feb 24, 2025

Profile

SI-BONE, Inc., a medical device company, develops implantable devices used to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers iFuse, a minimally invasive surgical implant system to address sacroiliac joint dysfunction and degeneration, adult deformity, and pelvic ring traumatic fractures. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; and iFuse-TORQ, a set of 3D-printed threaded implants designed to treat fractures of the pelvis and for minimally invasive sacroiliac joint fusion. It markets its products primarily with a direct sales force, as well as through distributors. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
URL
https://si-bone.com/
IPO date
Oct 17, 2018
Employees
357
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
138,886
30.52%
106,409
18.03%
Cost of revenue
185,817
166,018
Unusual Expense (Income)
NOPBT
(46,931)
(59,609)
NOPBT Margin
Operating Taxes
1,647
Tax Rate
NOPAT
(46,931)
(61,256)
Net income
(43,336)
-31.11%
(62,903)
4.62%
Dividends
Dividend yield
Proceeds from repurchase of equity
83,671
4,015
BB yield
-10.37%
-0.86%
Debt
Debt current
2,832
1,388
Long-term debt
40,503
42,301
Deferred revenue
Other long-term liabilities
18
30
Net debt
(122,684)
(53,601)
Cash flow
Cash from operating activities
(18,713)
(41,655)
CAPEX
(7,799)
(9,507)
Cash from investing activities
(59,798)
(2,815)
Cash from financing activities
90,933
2,197
FCF
(50,291)
(73,777)
Balance
Cash
166,019
97,290
Long term investments
Excess cash
159,075
91,970
Stockholders' equity
(400,102)
98,302
Invested Capital
609,903
45,792
ROIC
ROCE
EV
Common stock shares outstanding
38,427
34,202
Price
20.99
54.34%
13.60
-38.77%
Market cap
806,592
73.41%
465,145
-36.82%
EV
683,908
411,544
EBITDA
(41,503)
(56,157)
EV/EBITDA
Interest
3,462
2,819
Interest/NOPBT